Price Performance of Revance Therapeutics, Inc. (RVNC)
When considering this stock’s price journey, Revance Therapeutics, Inc. (NASDAQ:RVNC) has had quite the interesting last 12 months. This stock reaches its lowest price point, which was $15.07, on 03/18/19, but also managed to go to its highest price point of $34.20 on 04/19/18.
At the end of the most recent trading day, Revance Therapeutics, Inc. closed at $15.47. The stock began the trading session at $15.91 and hit a high of $15.98. The lowest price during the trading day was $15.41.
The shares of this company, which operates in the healthcare sector, reached a trading volume of about 358,373 throughout the day, which was clearly lower than the average daily volume for these shares.
At the time of writing, this publicly-traded organization holds a total market value of 686.40M, with 170 employees on its payroll.
Keeping on the same track, if we take into consideration what all the top market analysts are rating for Revance Therapeutics, Inc. (NASDAQ:RVNC), the average analyst opinion is 1.90. How is that calculated? Well, 3 analysts have given this company a BUY rating, 5 are rated it as OUTPERFORM, 2 have recommended that investors HOLD, 0 are considering it an UNDERPERFORM and 0 have recommended that owners of these shares SELL.
A month ago, 3 analysts thought this stock was a BUY, 7 of them posted an OUTPERFORM rating, 2 analysts recommended to HOLD this stock, 0 of them provided an underperform rating and 0 rated it as a Sell.
This company’s 100-day moving average was 19.18, while its price change was posted at -7.12. Similarly, Revance Therapeutics, Inc. (NASDAQ:RVNC) experienced a 100-day Percent movement of -31.52% with a trading volume reaching 414,476.
Continuing to look at similarly important data, this stock’s distance from its 200-day Simple Moving Average, or SMA 200, is -33.27% at the time of writing. This organization’s revenue over the trailing twelve months (TTM) of active operations is 3.70M, considering the fact that it was able to rack up the income of -$142.60M through that period of time.
Another thing we can do is divide a firm’s current liabilities by its stockholders’ equity value, which figures out to be its Total Debt to Equity Ratio (D/E Ratio, as it’s sometimes called), which is a solid method for illustrating the organization’s financial strength. This metric just illustrates how much debt an organization is using to support its assets in relation to how much its shareholder’s equity is worth. RVNC’s Total Dept/Eq ratio is sitting at 0.00 at the time of writing, while its long-term Dept/Eq ratio is 0.00
While maintaining our attention on the Technical analysis of Revance Therapeutics, Inc. (NASDAQ:RVNC), during the last 50 days, its Raw Stochastic average was observed 7.33%, representing a downgrade from this organization’s 20-day Raw Stochastic average – which was posted 14.23%. During the last 20-days time span, this firm’s Stochastic %K was 24.10% and its Stochastic %D was noted 29.79%.
We can get a good view of observable moving trends by taking a glance at the past price performance exhibited by Revance Therapeutics, Inc. (NASDAQ:RVNC) stock. This particular stock’s current year-to-date (YTD) price performance is standing at -23.15%. Meanwhile, during the past six months of trading, this stock has deteriorated to -35.54%, along with a full-year performance of -50.73%. This company’s shares increased nearly 9.08% during the last 7-day stretch and up 0.13% over the last 30 days.